| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 27 | 2024 | 2755 | 2.470 |
Why?
|
| Mutation | 33 | 2024 | 5767 | 2.230 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2025 | 194 | 1.770 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2024 | 164 | 1.620 |
Why?
|
| Brain Neoplasms | 14 | 2023 | 1236 | 1.410 |
Why?
|
| Genomics | 19 | 2024 | 1474 | 1.370 |
Why?
|
| Precision Medicine | 7 | 2024 | 306 | 1.260 |
Why?
|
| Xanthogranuloma, Juvenile | 3 | 2017 | 31 | 1.140 |
Why?
|
| Glioma | 7 | 2025 | 496 | 1.130 |
Why?
|
| Histiocytosis, Langerhans-Cell | 5 | 2018 | 221 | 1.110 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2024 | 426 | 1.110 |
Why?
|
| Medulloblastoma | 5 | 2020 | 338 | 1.070 |
Why?
|
| Medical Oncology | 5 | 2024 | 214 | 1.050 |
Why?
|
| Biomarkers, Tumor | 6 | 2023 | 1439 | 1.050 |
Why?
|
| Pyrimidines | 4 | 2025 | 375 | 1.030 |
Why?
|
| Child | 51 | 2025 | 24228 | 1.010 |
Why?
|
| Circulating Tumor DNA | 2 | 2023 | 32 | 1.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2023 | 862 | 0.930 |
Why?
|
| DNA, Neoplasm | 4 | 2020 | 300 | 0.920 |
Why?
|
| Glioblastoma | 6 | 2015 | 334 | 0.880 |
Why?
|
| Molecular Targeted Therapy | 8 | 2022 | 352 | 0.870 |
Why?
|
| Germ-Line Mutation | 10 | 2024 | 313 | 0.800 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 467 | 0.790 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2021 | 130 | 0.770 |
Why?
|
| Colorectal Neoplasms | 13 | 2022 | 561 | 0.770 |
Why?
|
| DNA Copy Number Variations | 5 | 2022 | 940 | 0.770 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 432 | 0.770 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2009 | 74 | 0.760 |
Why?
|
| MyoD Protein | 1 | 2021 | 21 | 0.760 |
Why?
|
| Young Adult | 19 | 2025 | 8855 | 0.740 |
Why?
|
| Benzimidazoles | 1 | 2022 | 129 | 0.740 |
Why?
|
| DNA Mutational Analysis | 9 | 2019 | 790 | 0.740 |
Why?
|
| Child, Preschool | 23 | 2025 | 13888 | 0.720 |
Why?
|
| Humans | 104 | 2025 | 123103 | 0.720 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 375 | 0.700 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 77 | 0.680 |
Why?
|
| Sequence Analysis, DNA | 12 | 2022 | 1751 | 0.670 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 886 | 0.660 |
Why?
|
| Adolescent | 26 | 2025 | 19094 | 0.660 |
Why?
|
| Cerebellar Neoplasms | 5 | 2020 | 282 | 0.650 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 200 | 0.620 |
Why?
|
| Infant | 18 | 2025 | 12357 | 0.610 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 197 | 0.600 |
Why?
|
| Erdheim-Chester Disease | 2 | 2015 | 23 | 0.590 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2015 | 39 | 0.590 |
Why?
|
| MAP Kinase Signaling System | 5 | 2024 | 315 | 0.580 |
Why?
|
| Histiocytes | 1 | 2017 | 23 | 0.570 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 113 | 0.550 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2024 | 3076 | 0.540 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2015 | 244 | 0.530 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2024 | 28 | 0.520 |
Why?
|
| Ependymoma | 3 | 2022 | 134 | 0.520 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 20 | 0.510 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2016 | 98 | 0.500 |
Why?
|
| Genes, Neoplasm | 4 | 2010 | 80 | 0.500 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 548 | 0.490 |
Why?
|
| Lymph Nodes | 1 | 2017 | 376 | 0.490 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 101 | 0.480 |
Why?
|
| Vincristine | 1 | 2015 | 196 | 0.470 |
Why?
|
| Nerve Tissue Proteins | 8 | 2017 | 1112 | 0.470 |
Why?
|
| Exome | 7 | 2024 | 1040 | 0.470 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 128 | 0.460 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 240 | 0.460 |
Why?
|
| Male | 39 | 2025 | 60129 | 0.440 |
Why?
|
| Repressor Proteins | 2 | 2015 | 816 | 0.440 |
Why?
|
| Incidental Findings | 1 | 2014 | 125 | 0.430 |
Why?
|
| Genetics, Medical | 1 | 2014 | 116 | 0.430 |
Why?
|
| Antineoplastic Agents | 6 | 2024 | 1660 | 0.430 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2010 | 202 | 0.430 |
Why?
|
| Female | 41 | 2025 | 65514 | 0.420 |
Why?
|
| DNA Methylation | 3 | 2022 | 989 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2017 | 2587 | 0.410 |
Why?
|
| Genetic Counseling | 3 | 2018 | 225 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 1872 | 0.410 |
Why?
|
| Genome, Human | 8 | 2018 | 1264 | 0.400 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2024 | 206 | 0.400 |
Why?
|
| Pyrazoles | 3 | 2025 | 304 | 0.370 |
Why?
|
| Adult | 25 | 2025 | 29009 | 0.370 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2025 | 197 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1118 | 0.360 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1593 | 0.360 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 340 | 0.360 |
Why?
|
| Oncologists | 2 | 2023 | 29 | 0.360 |
Why?
|
| Transcription Factors | 5 | 2025 | 2585 | 0.350 |
Why?
|
| RNA, Messenger | 2 | 2015 | 2809 | 0.340 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2022 | 70 | 0.340 |
Why?
|
| Sarcoma | 3 | 2018 | 194 | 0.340 |
Why?
|
| Astrocytoma | 2 | 2009 | 103 | 0.330 |
Why?
|
| Oncogenes | 1 | 2010 | 168 | 0.330 |
Why?
|
| Parents | 3 | 2024 | 1033 | 0.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2025 | 528 | 0.330 |
Why?
|
| Biomedical Research | 4 | 2021 | 516 | 0.320 |
Why?
|
| Signal Transduction | 9 | 2024 | 4493 | 0.320 |
Why?
|
| Gene Dosage | 6 | 2018 | 440 | 0.310 |
Why?
|
| DNA-Binding Proteins | 8 | 2024 | 2055 | 0.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 805 | 0.300 |
Why?
|
| Disclosure | 3 | 2019 | 154 | 0.290 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 2 | 1998 | 22 | 0.290 |
Why?
|
| Drug Therapy | 2 | 2018 | 85 | 0.280 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 668 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1258 | 0.280 |
Why?
|
| Gangliosides | 2 | 2025 | 63 | 0.280 |
Why?
|
| Muscular Atrophy, Spinal | 4 | 2000 | 43 | 0.270 |
Why?
|
| Frameshift Mutation | 4 | 2011 | 175 | 0.270 |
Why?
|
| Pediatrics | 3 | 2021 | 1141 | 0.260 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 1311 | 0.250 |
Why?
|
| Decision Making | 4 | 2024 | 651 | 0.250 |
Why?
|
| Exons | 8 | 2009 | 794 | 0.250 |
Why?
|
| Receptor, trkA | 1 | 2025 | 16 | 0.240 |
Why?
|
| Research Subjects | 2 | 2015 | 55 | 0.240 |
Why?
|
| Phthalazines | 1 | 2024 | 14 | 0.230 |
Why?
|
| United States | 8 | 2024 | 10651 | 0.230 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 39 | 0.230 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2024 | 58 | 0.230 |
Why?
|
| Interleukin-15 | 1 | 2025 | 91 | 0.230 |
Why?
|
| Aminopyridines | 1 | 2024 | 53 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2025 | 524 | 0.220 |
Why?
|
| Prognosis | 5 | 2025 | 4512 | 0.220 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 49 | 0.220 |
Why?
|
| Meningioma | 1 | 2025 | 120 | 0.220 |
Why?
|
| Genetic Testing | 5 | 2024 | 996 | 0.210 |
Why?
|
| Clinical Protocols | 2 | 2022 | 234 | 0.210 |
Why?
|
| Meningeal Neoplasms | 1 | 2025 | 183 | 0.210 |
Why?
|
| Pancreatic Neoplasms | 4 | 2009 | 676 | 0.210 |
Why?
|
| Mutation, Missense | 6 | 2014 | 849 | 0.210 |
Why?
|
| Pyrroles | 1 | 2024 | 178 | 0.210 |
Why?
|
| Piperazines | 1 | 2024 | 230 | 0.200 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 1679 | 0.200 |
Why?
|
| Symporters | 1 | 2022 | 66 | 0.200 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 16 | 0.200 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 61 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 83 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 5 | 2006 | 1584 | 0.190 |
Why?
|
| Hepatoblastoma | 2 | 2016 | 179 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 819 | 0.190 |
Why?
|
| Web Browser | 1 | 2021 | 8 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 488 | 0.190 |
Why?
|
| Multilingualism | 2 | 2018 | 43 | 0.190 |
Why?
|
| Ribonuclease III | 1 | 2022 | 87 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 155 | 0.180 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 54 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 118 | 0.180 |
Why?
|
| DNA Repair | 1 | 2024 | 579 | 0.180 |
Why?
|
| Trans-Activators | 1 | 2025 | 809 | 0.180 |
Why?
|
| Supratentorial Neoplasms | 1 | 2021 | 37 | 0.180 |
Why?
|
| Quinolines | 1 | 2021 | 96 | 0.180 |
Why?
|
| Craniopharyngioma | 1 | 2020 | 33 | 0.180 |
Why?
|
| Professional-Family Relations | 2 | 2018 | 95 | 0.180 |
Why?
|
| Clonal Evolution | 1 | 2020 | 38 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2023 | 756 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2021 | 1158 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 43 | 0.170 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 61 | 0.170 |
Why?
|
| Imidazoles | 1 | 2021 | 193 | 0.170 |
Why?
|
| Myofibromatosis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 19 | 0.170 |
Why?
|
| Neuroblastoma | 1 | 2025 | 513 | 0.170 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 44 | 0.170 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 19 | 0.170 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 29 | 0.170 |
Why?
|
| Gene Amplification | 3 | 2008 | 228 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 218 | 0.160 |
Why?
|
| Breast Neoplasms | 6 | 2009 | 2479 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1290 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 400 | 0.160 |
Why?
|
| Phenotype | 6 | 2019 | 4226 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2020 | 221 | 0.160 |
Why?
|
| Founder Effect | 1 | 1998 | 31 | 0.160 |
Why?
|
| Software | 2 | 2021 | 674 | 0.160 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 183 | 0.150 |
Why?
|
| Genome | 1 | 2021 | 474 | 0.150 |
Why?
|
| Empathy | 1 | 2018 | 57 | 0.150 |
Why?
|
| Osteopontin | 1 | 2018 | 49 | 0.150 |
Why?
|
| Cultural Competency | 1 | 2018 | 52 | 0.150 |
Why?
|
| Nuclear Proteins | 3 | 2023 | 1268 | 0.150 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 74 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 1012 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 408 | 0.150 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.150 |
Why?
|
| Communication | 2 | 2018 | 513 | 0.140 |
Why?
|
| SMN Complex Proteins | 6 | 2000 | 6 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2018 | 135 | 0.140 |
Why?
|
| Antigens, Nuclear | 1 | 2017 | 61 | 0.140 |
Why?
|
| Language | 1 | 2018 | 201 | 0.140 |
Why?
|
| Leukemia | 1 | 2020 | 375 | 0.140 |
Why?
|
| Enzyme Activation | 2 | 2016 | 617 | 0.140 |
Why?
|
| Neoplasm Grading | 3 | 2025 | 268 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2017 | 17 | 0.140 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 6 | 2000 | 110 | 0.140 |
Why?
|
| Data Curation | 1 | 2016 | 12 | 0.140 |
Why?
|
| Genes, p53 | 2 | 2015 | 213 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 1080 | 0.140 |
Why?
|
| Remission Induction | 1 | 2017 | 300 | 0.140 |
Why?
|
| Everolimus | 1 | 2016 | 46 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2017 | 102 | 0.130 |
Why?
|
| Haploinsufficiency | 1 | 2017 | 247 | 0.130 |
Why?
|
| Language Development Disorders | 1 | 2017 | 173 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2017 | 229 | 0.130 |
Why?
|
| Tandem Repeat Sequences | 1 | 2015 | 37 | 0.130 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 244 | 0.130 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 238 | 0.120 |
Why?
|
| Parenting | 1 | 2019 | 328 | 0.120 |
Why?
|
| Receptor, trkB | 3 | 2025 | 20 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2015 | 312 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 110 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 253 | 0.120 |
Why?
|
| Sirolimus | 1 | 2016 | 220 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 781 | 0.120 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 22 | 0.120 |
Why?
|
| Cyclin B | 1 | 2014 | 23 | 0.120 |
Why?
|
| Cells, Cultured | 2 | 2017 | 3040 | 0.120 |
Why?
|
| Exsanguination | 1 | 2014 | 2 | 0.120 |
Why?
|
| Telomere-Binding Proteins | 1 | 2014 | 44 | 0.120 |
Why?
|
| Microcephaly | 1 | 2017 | 328 | 0.120 |
Why?
|
| Survival Rate | 2 | 2010 | 1999 | 0.120 |
Why?
|
| Genetic Research | 1 | 2015 | 56 | 0.120 |
Why?
|
| Histiocytosis, Sinus | 1 | 2014 | 31 | 0.110 |
Why?
|
| Death | 1 | 2015 | 70 | 0.110 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 32 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 142 | 0.110 |
Why?
|
| Gene Duplication | 1 | 2015 | 358 | 0.110 |
Why?
|
| Consensus | 2 | 2019 | 607 | 0.110 |
Why?
|
| Point Mutation | 3 | 2010 | 348 | 0.110 |
Why?
|
| RNA-Binding Proteins | 6 | 2000 | 576 | 0.100 |
Why?
|
| Quality of Life | 1 | 2022 | 1923 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 938 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2020 | 8106 | 0.100 |
Why?
|
| Mice | 6 | 2021 | 17537 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 996 | 0.100 |
Why?
|
| Informed Consent | 1 | 2015 | 341 | 0.100 |
Why?
|
| Ethics, Medical | 1 | 2015 | 395 | 0.100 |
Why?
|
| Age Factors | 2 | 2016 | 2799 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 683 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2017 | 3234 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2014 | 741 | 0.100 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2011 | 24 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1688 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 993 | 0.100 |
Why?
|
| Animals | 9 | 2021 | 33792 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2014 | 403 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2017 | 962 | 0.090 |
Why?
|
| Algorithms | 5 | 2022 | 1598 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5039 | 0.090 |
Why?
|
| Tourniquets | 1 | 2011 | 10 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1909 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 48 | 0.090 |
Why?
|
| Genotype | 3 | 2015 | 2533 | 0.090 |
Why?
|
| Germ Cells | 2 | 2024 | 192 | 0.090 |
Why?
|
| Membrane Glycoproteins | 2 | 2025 | 411 | 0.090 |
Why?
|
| Middle Aged | 10 | 2025 | 25992 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 1004 | 0.090 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2011 | 126 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2112 | 0.090 |
Why?
|
| Disease Progression | 2 | 2014 | 2028 | 0.090 |
Why?
|
| Extremities | 1 | 2011 | 83 | 0.090 |
Why?
|
| Methylation | 1 | 2010 | 226 | 0.090 |
Why?
|
| Sodium Channels | 1 | 2011 | 109 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1638 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2016 | 1479 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 153 | 0.080 |
Why?
|
| Texas | 3 | 2024 | 3563 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 469 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 3 | 2007 | 752 | 0.080 |
Why?
|
| Smad4 Protein | 1 | 2009 | 55 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2025 | 16044 | 0.080 |
Why?
|
| Translating | 2 | 2018 | 31 | 0.080 |
Why?
|
| Chromatin | 1 | 2011 | 554 | 0.080 |
Why?
|
| Receptor, trkC | 2 | 2025 | 4 | 0.080 |
Why?
|
| HLA-A Antigens | 1 | 2008 | 35 | 0.070 |
Why?
|
| Family | 2 | 2024 | 571 | 0.070 |
Why?
|
| National Human Genome Research Institute (U.S.) | 2 | 2018 | 17 | 0.070 |
Why?
|
| Aged | 8 | 2025 | 19093 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1522 | 0.070 |
Why?
|
| Histones | 1 | 2010 | 527 | 0.070 |
Why?
|
| Homozygote | 1 | 2008 | 532 | 0.070 |
Why?
|
| Consensus Sequence | 1 | 2006 | 59 | 0.070 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 3867 | 0.070 |
Why?
|
| Sequence Deletion | 3 | 2009 | 527 | 0.070 |
Why?
|
| Patients | 2 | 2018 | 121 | 0.070 |
Why?
|
| Survival of Motor Neuron 2 Protein | 4 | 2000 | 13 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 434 | 0.060 |
Why?
|
| Survival of Motor Neuron 1 Protein | 4 | 2000 | 20 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 825 | 0.060 |
Why?
|
| Recurrence | 2 | 2022 | 1419 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 538 | 0.060 |
Why?
|
| Biopsy | 2 | 2020 | 1236 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2009 | 792 | 0.060 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 428 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 57 | 0.060 |
Why?
|
| Gene Fusion | 1 | 2025 | 55 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.060 |
Why?
|
| Computational Biology | 5 | 2008 | 804 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 43 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 28 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 67 | 0.060 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2017 | 120 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 80 | 0.060 |
Why?
|
| Chromosomal Instability | 1 | 2004 | 58 | 0.060 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 93 | 0.060 |
Why?
|
| Tyrosine | 1 | 2004 | 152 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2010 | 827 | 0.060 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 35 | 0.060 |
Why?
|
| Natural Killer T-Cells | 1 | 2025 | 81 | 0.060 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 57 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 1030 | 0.050 |
Why?
|
| Benzamides | 1 | 2023 | 106 | 0.050 |
Why?
|
| Alleles | 2 | 1998 | 1603 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3664 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 37 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 54 | 0.050 |
Why?
|
| Oligodendroglioma | 2 | 2014 | 24 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 224 | 0.050 |
Why?
|
| Centromere | 2 | 2000 | 107 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 211 | 0.050 |
Why?
|
| Nucleic Acid Heteroduplexes | 2 | 1998 | 17 | 0.050 |
Why?
|
| DNA Damage | 1 | 2024 | 512 | 0.050 |
Why?
|
| Pedigree | 3 | 2014 | 1576 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2015 | 399 | 0.040 |
Why?
|
| Physicians | 2 | 2018 | 583 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 3291 | 0.040 |
Why?
|
| Training Support | 1 | 2020 | 17 | 0.040 |
Why?
|
| Patient Participation | 1 | 2023 | 220 | 0.040 |
Why?
|
| Databases, Genetic | 2 | 2016 | 470 | 0.040 |
Why?
|
| Financing, Government | 1 | 2020 | 30 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4283 | 0.040 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 83 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 63 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 133 | 0.040 |
Why?
|
| Cell Line | 2 | 2019 | 2771 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2019 | 54 | 0.040 |
Why?
|
| Pediatricians | 1 | 2020 | 65 | 0.040 |
Why?
|
| Transcriptome | 2 | 2018 | 903 | 0.040 |
Why?
|
| Heteroduplex Analysis | 1 | 1998 | 4 | 0.040 |
Why?
|
| Social Responsibility | 1 | 2019 | 79 | 0.040 |
Why?
|
| Linguistics | 1 | 2018 | 18 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 144 | 0.040 |
Why?
|
| Career Choice | 1 | 2020 | 144 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 593 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2018 | 39 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 326 | 0.040 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Mentors | 1 | 2020 | 145 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 1998 | 134 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 664 | 0.040 |
Why?
|
| Social Behavior | 1 | 2019 | 207 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 101 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 350 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 19 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2307 | 0.040 |
Why?
|
| Telomere | 1 | 1998 | 206 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2025 | 12115 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 38 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2017 | 48 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 54 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 60 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1386 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1999 | 349 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 1997 | 75 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 70 | 0.030 |
Why?
|
| Larva | 1 | 2017 | 247 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 281 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 324 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1997 | 117 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2017 | 100 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 133 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 137 | 0.030 |
Why?
|
| Heterozygote | 1 | 1998 | 678 | 0.030 |
Why?
|
| Population Groups | 1 | 2016 | 29 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 500 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 718 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 151 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 179 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 233 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1998 | 807 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 369 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2015 | 99 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1306 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2015 | 59 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 161 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 190 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 880 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 614 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2017 | 381 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 386 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 715 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 257 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 139 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2007 | 2695 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1236 | 0.030 |
Why?
|
| Military Medicine | 1 | 2014 | 47 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 533 | 0.030 |
Why?
|
| Bandages | 1 | 2014 | 55 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 676 | 0.030 |
Why?
|
| Manikins | 1 | 2014 | 134 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 606 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1876 | 0.030 |
Why?
|
| Patched Receptors | 1 | 2011 | 26 | 0.020 |
Why?
|
| Patched-1 Receptor | 1 | 2011 | 33 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2011 | 36 | 0.020 |
Why?
|
| Base Sequence | 2 | 2011 | 3091 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1305 | 0.020 |
Why?
|
| Ouabain | 1 | 2011 | 27 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2011 | 219 | 0.020 |
Why?
|
| Digoxin | 1 | 2011 | 41 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2011 | 192 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 196 | 0.020 |
Why?
|
| Pancreas | 1 | 2011 | 211 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 364 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2007 | 1081 | 0.020 |
Why?
|
| Breast | 1 | 2011 | 214 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2011 | 159 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2011 | 158 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2009 | 1 | 0.020 |
Why?
|
| Stomach | 1 | 2011 | 272 | 0.020 |
Why?
|
| Codon, Terminator | 1 | 2009 | 26 | 0.020 |
Why?
|
| Colon | 1 | 2011 | 352 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 96 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 2943 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 107 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2011 | 485 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2008 | 25 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 4699 | 0.020 |
Why?
|
| Motor Neurons | 2 | 2000 | 139 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 1938 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2011 | 458 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1473 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 1061 | 0.020 |
Why?
|
| Spinal Cord | 2 | 2000 | 305 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 151 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 184 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 657 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 2967 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2006 | 69 | 0.020 |
Why?
|
| Epitopes | 1 | 2008 | 429 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1213 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 393 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2008 | 1070 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 718 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 3 | 1 | 2004 | 1 | 0.010 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2004 | 8 | 0.010 |
Why?
|
| MRE11 Homologue Protein | 1 | 2004 | 4 | 0.010 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2004 | 29 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1782 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 6219 | 0.010 |
Why?
|
| Markov Chains | 1 | 2004 | 83 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1862 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 158 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2004 | 131 | 0.010 |
Why?
|
| Fusion Proteins, gag-onc | 1 | 2003 | 1 | 0.010 |
Why?
|
| Receptor, EphA3 | 1 | 2003 | 1 | 0.010 |
Why?
|
| Guanylate Cyclase | 1 | 2003 | 37 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 66 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 780 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 1442 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 1312 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 1068 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1610 | 0.010 |
Why?
|
| Microinjections | 1 | 2000 | 52 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 643 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 258 | 0.010 |
Why?
|
| Brain Stem | 1 | 2000 | 115 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2004 | 744 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2000 | 966 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 6374 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2000 | 1100 | 0.010 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1997 | 44 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2000 | 991 | 0.010 |
Why?
|
| DNA Primers | 1 | 1997 | 660 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 892 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 2394 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1702 | 0.010 |
Why?
|
| DNA | 1 | 1997 | 1588 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1997 | 3325 | 0.000 |
Why?
|